Vasculitis

The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.JAK inhibitor Treatment of…

It has been easy over time to presume that all advanced therapies in a disease area will work as well as each other. We have been so used to the idea that all b/tsDMARDs in rheumatoid arthritis are…

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years…